enGene Holdings Inc. (NASDAQ:ENGNW) Short Interest Up 783.3% in February

enGene Holdings Inc. (NASDAQ:ENGNW) saw a significant growth in short interest in February. As of February 13th, there was short interest totaling 9,849 shares, a growth of 783.3% from the January 29th total of 1,115 shares. Based on an average trading volume of 12,823 shares, the short-interest ratio is presently 0.8 days. Based on an average trading volume of 12,823 shares, the short-interest ratio is presently 0.8 days.

enGene Stock Up 9.2%

Shares of NASDAQ ENGNW opened at $3.57 on Thursday. enGene has a 1-year low of $0.51 and a 1-year high of $4.20. The company has a fifty day moving average price of $3.12 and a 200 day moving average price of $2.11.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.